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Purpose/Objective: Whilst moderate hypofractionation 
radiation therapy (HFRT) is routinely used in many European 
centres data supporting its use in Indians is unavailable. 
Indian patients were likely to present with more advanced 
disease and there are questions on biological dissimalirity 
between Caucasians and Indians. This analyses reports the 
demographic data, toxicity profile and control outcomes of 
the breast cancer patients. 
Materials and Methods: From May 2011 to January 2014, 496 
patients with breast cancer underwent HFRT with 3DCRT 
(4005cGy in 15 fractions) to whole breast or chest wall 
and/or supraclavicular fossa following curative surgery. The 
demographic data with respect to age, sex, neoadjuvant 
chemotherapy, type of surgery(modified radical mastectomy 
(MRM) vs Breast conservation surgery (BCS), histopathology 
(grade, tumour size, nodal status, ER/PR/Her2Neu status, 
margins and LVI), Nottingham Prognostic Index score (NPI) 
and Cambridge score were analyzed. Locoregional (LRR) and 
distant failures were analyzed using Kaplan Meier curves, 
univariate and multivariate analyses was done using the Cox 
regression model to identify predictors of failure.  
Results: The mean age at presentation was 52 years (23 – 88 
years) and 206 patients (41.6 % ) had breast conservation 
surgery. Patients who are younger than 40 years had higher 
rates of breast conservation surgery (p=0.01) irrespective of 
the tumour size. The histopathological variables and 
prognostic indexes were not significantly different across 
various age groups. The hypofractionated radiation therapy 
was well tolerated with 1.2 % and 7.1% having grade 3 and 2 
acute skin toxicity. At 6 months 13.5% had Gr 1 and 1.6% Gr 2 
lymphoedema, 5% reported distortion with no reported long 
term pneumonitis or cardiac complications. The median 
follow up period was 18.5 months. 90.2 % of the patients 
were on regular follow up. The crude LRR and distant failure 
rate was 3.42% (17 patients) and 7.66% (38 patients). In 
patients who failed loco-regionally had higher NPI score, 
greater than 70 % had node positive, tumour size > 2 cm, Gr 3 
tumours. In univariate Cox regression analysis, patients with 
positive nodal status (p=0.007), grade 3(p=0.003), MRM 
(p=0.034) and triple negative status (p=0.027) had significant 
higher distant failure rates while nodal status (p=0.005) alone 
stood significant risk factor for LRR. In multivariate analysis, 
node positivity was remained significant for locoregional 
recurrence but none of the factors were significant for 
distant metastases. The actuarial locoregional failure and 
distant metastases at 2 years were 3.4 % and 11.2% 
respectively 
Conclusions: HFRT was well tolerated and loco-regional and 
distant failure rates were comparable to the published data 
establishing its safety and effectiveness in Indian population. 
Node positivity, grade 3 and triple negative tumours are more 
aggressive and tend to have higher locoregional and distant 
failure.  
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Purpose/Objective: To report the distribution of 
radiotherapy dose within the heart of women irradiated for 
breast cancer in Sweden and Denmark between 1958 and 
2001, who later developed a major coronary event. In the 
future, these doses will be used to assess the association 
between the spatial distribution of radiation dose in the 
heart and the location of cardiac damage. 
Materials and Methods: 487 women irradiated for breast 
cancer between 1958 and 2001 and who subsequently 
developed a major coronary event with known location of 
cardiac damage were included in the study. Each woman's 
radiotherapy chart was reviewed, and categorised according 
to the regimen used. The four most commonly used 
treatment regimens were reconstructed on 10 randomly 
selected CT planning scans of women irradiated for breast 
cancer at Odense University Hospital in the year 2010. One 
representative patient was selected who was typical for 
mean cardiac doses. All regimens identified were then 
reconstructed on the representative patient. Doses were 
extracted from dose volume histograms for five left 
ventricular and ten coronary arterial segments, which 
matched the different sites of cardiac damage for the women 
studied. Several sources of dosimetric uncertainty were 
considered. 
Results: 31 regimens were identified and these were further 
categorised into six: left and right tangential irradiation, left 
and right direct electron or orthovoltage irradiation and left 
and right direct megavoltage regimens. The estimated mean 
heart dose ranged from 3-27Gy for left-sided treatment and 
0.6-27Gy for right-sided treatment. Doses to different 
segments of the left ventricle varied substantially e.g. left 
tangential irradiation delivered 10-48Gy to the apex but only 
0.3-5Gy to the inferior segment. Coronary artery doses also 
varied between regimens. Left-sided regimens resulted in 
highest doses (3-46Gy) to the left anterior descending 
coronary artery whereas right-sided regimens gave highest 
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doses to the right coronary artery (0.4-35Gy). Analyses of 
cardiac doses for the 10 randomly selected CT scans showed 
considerable inter-patient dose variation for left tangential 
radiotherapy but less variability for left direct beams. 
Conclusions: Doses to cardiac structures varied considerably 
depending on the regimen used. These doses can be used to 
assess which parts of the heart generally received higher 
doses relative to other parts of the heart. For example, left 
sided tangential radiotherapy tended to give higher doses to 
the apex compared with the other ventricular segments. Left 
sided regimens tended to deliver high radiation doses to the 
left anterior descending coronary artery, and right-sided 
regimens tended to deliver high doses to the right coronary 
artery. 
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Purpose/Objective: Neo-adjuvant radiation in rectal cancer 
improves R0 resection rates and reduces local relapse. ESMO 
and UK National Institute of Clinical Excellence (NICE) 
guidance advocate consideration of short course radiotherapy 
(SCRT) or long course chemoradiotherapy (CRT) for 
intermediate risk rectal cancer and CRT for high risk 
tumours. However the Mercury group suggests only selected 
high risk tumours require neo-adjuvant CRT. As such there 
remains controversy regarding patient selection for radiation, 
with significant variations in current practise. Our use of 
radiotherapy over a 5-year period has mirrored Mercury 
guidance; we aim to assess the application of this guidance in 
a routine clinical setting. 
Materials and Methods: A retrospective analysis was 
performed, at a single tertiary referral centre, of patients 
receiving radical surgery for primary rectal cancer from 2007 
to 2012. Using multiple hospital electronic data-bases, we 
collected patient demographics, radiological TNM stage and 
CRM status, radiation delivered, pathological presence of 
extra mural vascular invasion (EMVI), R1 resection and local 
relapse rates. Risk stratification was based on the NICE 
criteria. 
Results: A total of 275 patients were identified. Of these, the 
proportion with T1, T2, T3 and T4 tumours was 12%, 17%, 58% 
and 13% respectively. The percentage of patients with N0, N1 
and N2 was 52%, 30% and 18% respectively. 1% of patients had 
low volume metastatic disease. 40% had threatened/involved 
CRM and 29% of the tumours had EMVI. Only 5% of the 
patients had R1 resection.The proportion with low, 
intermediate and high risk were 18%, 42% and 40% 
respectively. No patient received SCRT. 82% of the high risk 
patients and only 8% of intermediate risk received long 
course CRT.Median follow up was 54months (range 15 to 
60mths). 4 patients had synchronous metastases and hence 
were excluded from follow up. Of the remaining 271 
patients, the rate of local and distant recurrence was 2% and 
20% respectively. In the intermediate risk group, the R0 rate 
was 97% and the local relapse rate was 1.7%. 
Figure 1 depicts the proportion of patients receiving long 





Conclusions:This data concurs with the Mercury guidance 
that only selected high risk rectal cancer patients require 
CRT. Over a 5 year period despite the increasingly narrowed 
selection of patients for CRT we have maintained a local 
relapse rate of 2-5%.The intermediate risk group had 
acceptable R0 resection and local relapse rates; therefore we 
would suggest that there is no role for SCRT in rectal 
cancer.Lastly, due to the significant rate of distant relapse, 
our data concurs with current plans to investigate the role of 
neo-adjuvant chemotherapy in rectal cancer.  
   
 
 
 
